NovoCure NVCR Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $87.53M-6.4% | $93.55M-72.7% | $342.12M+129% | $149.62M+17.6% | $127.28M-22.3% | ||
| $344.48M-2.7% | $354.13M-48.8% | $691.38M-9.3% | $761.9M-5.0% | $801.85M+0.7% | ||
| $43.46M+5.7% | $41.11M+5.1% | $39.1M-2.8% | $40.21M+1.9% | $39.47M+12.5% | ||
| $631.66M-2.3% | $646.73M-46.1% | $1.2B+10.8% | $1.08B-0.6% | $1.09B-1.6% | ||
| $76.28M-1.7% | $77.61M-3.0% | $79.98M-0.4% | $80.33M+0.9% | $79.6M+2.5% | ||
| $156.26M-0.8% | $157.6M-2.3% | $161.34M-0.8% | $162.58M+1.9% | $159.51M+18.9% | ||
| $787.93M-2.0% | $804.33M-40.9% | $1.36B+9.3% | $1.25B-0.2% | $1.25B+0.6% | ||
| $127.24M+4.1% | $122.23M+2.8% | $118.92M+14.7% | $103.68M+9.0% | $95.09M-9.5% | ||
| $217.58M-2.5% | $223.23M-71.2% | $776.01M+3.5% | $749.63M+0.9% | $743.31M-1.7% | ||
| $239.63M-0.4% | $240.63M-1.3% | $243.86M+66.1% | $146.8M+2.3% | $143.55M+15.6% | ||
| $457.21M-1.4% | $463.86M-54.5% | $1.02B+13.8% | $896.43M+1.1% | $886.85M+0.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$1.36B-5.5% | -$1.29B-1.9% | -$1.27B-3.0% | -$1.23B-3.4% | -$1.19B-3.0% | ||
| $330.72M-2.9% | $340.47M-0.3% | $341.33M-2.3% | $349.44M-3.5% | $361.96M+0.5% | ||
| $787.93M-2.0% | $804.33M-40.9% | $1.36B+9.3% | $1.25B-0.2% | $1.25B+0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NovoCure cover its short-term obligations?
- Its current ratio is 2.90 — current assets exceed current liabilities.
- Where does NovoCure's balance sheet data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.